Tag: seladelpar

Primary Biliary Cholangitis Treatment: What Works in 2026

Primary Biliary Cholangitis Treatment: What Works in 2026
Posted by: Alan Burity Vitulo in: Health and Medicine
27 Feb | 11:10 AM | 0

As of 2026, PBC treatment has shifted dramatically with the withdrawal of Ocaliva and the rise of seladelpar and elafibranor. Learn how UDCA remains first-line, what the new options do, and how to navigate treatment decisions.

read more
Go!

recent posts

Biologics in Severe Asthma: How Anti-IgE and Anti-IL-5 Therapies Change the Game
Biologics in Severe Asthma: How Anti-IgE and Anti-IL-5 Therapies Change the Game

Anti-IgE and anti-IL-5 biologics are transforming severe asthma care by targeting specific immune pathways. Learn how omalizumab, mepolizumab, and benralizumab reduce flare-ups, cut steroid use, and restore quality of life for those who don’t respond to standard treatments.

Published ON: 13 Feb
Linezolid and Tyramine: What You Need to Know About Diet and Hypertensive Risks
Linezolid and Tyramine: What You Need to Know About Diet and Hypertensive Risks

Linezolid can cause dangerous hypertensive reactions when combined with tyramine-rich foods like aged cheese or red wine. Learn what to avoid, how long the risk lasts, and how to stay safe during treatment.

Published ON: 24 Feb
Acupuncture for Pain: What Science Says About Traditional Needle Therapy
Acupuncture for Pain: What Science Says About Traditional Needle Therapy

Acupuncture for pain is backed by solid science, especially for chronic back pain, osteoarthritis, and headaches. It reduces pain without drugs, has minimal side effects, and works better than placebo in clinical trials. Learn how it works and who benefits most.

Published ON: 10 Feb
Primary Biliary Cholangitis Treatment: What Works in 2026
Primary Biliary Cholangitis Treatment: What Works in 2026

As of 2026, PBC treatment has shifted dramatically with the withdrawal of Ocaliva and the rise of seladelpar and elafibranor. Learn how UDCA remains first-line, what the new options do, and how to navigate treatment decisions.

Published ON: 27 Feb
C. difficile Colitis: Antibiotic Risks and Fecal Transplant Explained
C. difficile Colitis: Antibiotic Risks and Fecal Transplant Explained

C. difficile colitis is a serious infection triggered by antibiotics, causing severe diarrhea and recurring illness. Fecal transplants offer a 90% cure rate for recurrent cases, outperforming traditional antibiotics. Learn which drugs carry the highest risk and how microbiome therapy is changing treatment.

Published ON: 19 Feb

categories

archives

tags

dietary supplement medication safety treatment online pharmacy health benefits benefits online pharmacy Australia generic drugs role drug interactions calcium carbonate immune system sexual health potential treatment pain relief prevention heart health buspirone chronic pain exercise